Chronic Obstructive Pulmonary Disease | Access and Reimbursement | EU5 | 2016

The chronic obstructive pulmonary disease market is becoming increasingly crowded, and market access in the EU5 is a growing concern as manufacturers attempt to achieve favorable reimbursement status. In 2015, several new combination therapies have been approved for the treatment of COPD, payers are becoming stricter on HTA evaluations, requiring active comparators in clinical trials. Additionally, cost-conscious EU payers anticipate the launch of generic version of market leaders Spiriva and Seretide, which may displace or force these therapies to accept a lower price. Emerging FDCs will also compete against open combinations of older therapies, making favorable reimbursement a requirement to achieve market uptake.

Login to access report